Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Assistance Publique-Hopitaux De Paris holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 2 pending office actions. These actions are split across 2 distinct art units, suggesting that the company's intellectual property covers diverse technical ground within the pharmaceutical and biotech fields.
The prosecution involves 2 distinct examiners, with each examiner handling one of the pending matters. HOWARD, ZACHARY C is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending office action. This distribution shows that the 2 pending office actions are being reviewed independently by 2 distinct examiners, with no single examiner holding a majority of the workload.
For practitioners, the presence of 2 distinct art units and 2 distinct examiners requires a dual-track strategy. While the overall focus remains on Biotechnology & Pharmaceuticals, the firm must address the specific requirements of 2 different examiners. Since HOWARD, ZACHARY C is responsible for 1 of the 2 pending office actions, the prosecution team can dedicate equal attention to both active cases and their respective examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033479 | COMBINATION OF BIOMARKERS OF PRETERM DELIVERY | HOWARD, ZACHARY C | 5d overdue |
| 17595776 | DETECTION OF HYPERMETHYLATED GENES FOR DIAGNOSING PANCREATIC CANCER | TURPIN, ZACHARY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033479 | COMBINATION OF BIOMARKERS OF PRETERM DELIVERY | HOWARD, ZACHARY C | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033479 | COMBINATION OF BIOMARKERS OF PRETERM DELIVERY | HOWARD, ZACHARY C | 1674 | §102§112 | Final Rejection | 5d overdue | Pending | Apr 24, 2023 |
| 17595776 | DETECTION OF HYPERMETHYLATED GENES FOR DIAGNOSING PANCREATIC CANCER | TURPIN, ZACHARY MARK | 1682 | §103§112 | Final Rejection | — | Pending | Nov 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial